VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a note issued to investors on Thursday. The brokerage set a “sell” rating on the stock.

Separately, Cantor Fitzgerald reissued an “overweight” rating and set a $2.50 price objective on shares of VolitionRx in a research report on Thursday, May 16th.

VolitionRx Stock Up 4.9 %

Shares of NYSE VNRX opened at $0.71 on Thursday. The stock has a market capitalization of $58.64 million, a price-to-earnings ratio of -1.54 and a beta of 1.16. The stock’s fifty day simple moving average is $0.75 and its 200 day simple moving average is $0.84. VolitionRx has a 52-week low of $0.55 and a 52-week high of $1.79.

VolitionRx (NYSE:VNRX) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. The business had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $0.27 million. As a group, analysts anticipate that VolitionRx will post -0.34 earnings per share for the current year.

Institutional Trading of VolitionRx

An institutional investor recently bought a new position in VolitionRx stock. Silverberg Bernstein Capital Management LLC acquired a new position in VolitionRx Limited (NYSE:VNRX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned 0.19% of VolitionRx as of its most recent filing with the Securities and Exchange Commission (SEC). 8.09% of the stock is currently owned by hedge funds and other institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.